Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus EGFR TKI vs EGFR TKI alone for leptomeningeal metastasis from lung cancer
ChiCTR2000039917Phase 4Recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nimotuzumab in Carcinomatous Meningitis (CM) and bronchial carcinoma (2 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: Progression-free survival rate at 3 months. Started Dec 2020; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
Carcinomatous Meningitis (CM)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2000039917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039917.